UPMC invests in precision medicine, pop health with latest Omicia round of funding

HealthcareIT News – UPMC Enterprises, the innovation and commercialization arm of the healthcare giant, led Series B funding in precision medicine initiatives for Omicia, a clinical genome interpretation and reporting software company.

“As an investor, UPMC is excited to work with Omicia to begin to address today’s extraordinary opportunities in precision medicine,” Tal Heppenstall, president of UPMC Enterprises, said in a statement. “We envision a future in which we can routinely deliver actionable genomic insights about individual patients in real-time, within the workflow of our 3,500 physicians.”

Read full story.